Solventum Corporation (SOLV) Earnings

Management highlights

- Overall Quarterly Performance * The quarter delivered top-line and bottom-line results ahead of plan, with organic growth and EPS exceeding analyst expectations driven by strong operational execution. * Operating margins also outperformed expectations, and the company accelerated its $1 billion share repurchase program in line with its balanced capital allocation strategy. * Management confirmed the company is on track to achieve its long-range plan (LRP) earlier than initially expected. - Transformation Progress * The 3-phase transformation (stabilize/separate, reposition for growth, optimize portfolio) is running concurrently and all phases are progressing as planned. * Separation from 3M is in its final stages: ~70% of 200 transition service agreements have been exited, 950 of 1200 systems have been migrated (including most ERP implementations and all Solventum site conversions), with 90% of TSAs expected to be exited by end-2026. * Full completion of ERP cutover will remove operational complexity, free up talent and resources for innovation and margin expansion, and improve free cash flow. - Portfolio Optimization * The company officially announced a plan to separate the HIS business to maximize shareholder value: HIS is a strong, high-margin growing business that will achieve faster growth and greater AI innovation as a standalone entity or part of a scale healthcare IT player. Post-separation, Solventum will be a focused pure-play medtech company centered on Med-Surg and Dental. * The Acera tuck-in acquisition continues to outperform expectations, with year-over-year revenue growth above 40% and gross margins above 80%, aligning with the company's disciplined M&A playbook. * Purification and filtration divestiture activities remain on track, and the company will continue pursuing small, disciplined tuck-in acquisitions going forward. - Growth Driver & Innovation Progress * The company's 5 focused growth drivers represent a multi-billion dollar underpenetrated growth opportunity, most within Solventum's existing customer base. One example, IV site management's Tegaderm CHG reduces catheter-related bloodstream infections by 60% but is only used in less than 20% of eligible cases. * Innovation teams are aligned to growth drivers across segments: Med-Surg is focused on IV site management, negative pressure wound therapy, and sterilization assurance; Dental is focused on core restorative and aesthetic solutions; HIS continues innovating in AI-powered revenue cycle management. * A pipeline of ~20 new product launches are planned through Q1 2028, including major advanced wound care launches in H1 2027 and new dental aesthetic innovations starting in late 2026.

Guidance

- Organic sales growth guidance for full-year 2026 was tightened and raised to 2.5% to 3% (from the prior 2% to 3% range), or 3.5% to 4% after excluding the 100 basis point impact of planned SKU rationalization, representing an upward revision. Currency is still expected to add a 100 basis point favorable tailwind to full-year growth. - Operating margin guidance was raised to 22.2% to 22.7% (from the prior 21% to 21.5% range), including the full 120 basis point benefit from the recognized tariff refund. - Full-year EPS guidance was raised to $7.10 to $7.20 from the prior $6.40 to $6.60, an upward revision. - Full-year free cash flow guidance is revised to $200 million to $300 million, up from the prior estimate of ~$200 million, reflecting the benefit of the Q2 tariff refund. - The $125 million in Q2 ERP advanced orders and the $0.34 per share EPS benefit from those orders will mostly reverse in Q3 2026, leading to an expected Q3 organic sales growth range of -3% to -4%. Full-year 2026 guidance still includes the HIS segment, with updates on the separation's financial impact to come at a later date. - Management confirmed they expect to achieve long-range plan targets earlier than the original 2028 timeline, and expect organic growth to accelerate past 2026's guided 3.5% to 4% (ex-SKU) in 2027. - Non-operating expense expectations of ~$300 million and the expected effective tax rate range of 19.5% to 20.5% remained unchanged from prior guidance.

Segment performance

1. Med-Surg: $1.4 billion in sales, with 8.9% organic year-over-year growth. ERP advanced orders contributed ~700 basis points to growth, concentrated in infection prevention and surgical solutions. Advanced wound care grew 7.1% organically. Acera added $32 million to reported sales, growing 48% year-over-year. This segment accounts for approximately 63.6% of total company revenue. 2. Dental Solutions: $396 million in sales, with 15.2% organic year-over-year growth. ERP advanced orders contributed ~10 percentage points to growth, with underlying performance supported by new product launches. This segment accounts for approximately 18% of total company revenue. 3. Health Information Systems (HIS): $354 million in sales, with 5.4% organic year-over-year growth. Growth was driven by strong demand for revenue cycle management solutions, healthy customer retention, and consistent commercial execution. This segment accounts for approximately 16.1% of total company revenue.

Risks & headwinds

- The ERP cutover process creates temporary quarterly revenue and margin volatility, as companies pulled forward orders to mitigate potential disruption that will reverse in the subsequent quarter. Completing the cutover also requires significant managerial and operational focus that distracts from core growth initiatives until fully completed. - Forward-looking performance depends on successful completion of the 3M separation and ERP migration, and actual results could differ from management expectations due to unforeseen execution issues during the separation process. - The HIS separation process will create temporary separation-related costs that will impact financial results through the transaction timeline. - Industry-wide discussions of softening healthcare procedure demand and shifting utilization between inpatient and outpatient settings could impact future performance, though management has not yet seen this impact Solventum's business.

Analyst Q&A

• Q: Why is Solventum separating HIS despite it growing faster than the rest of the corporate average, how advanced is the process, and is the decision driven by outside interest?

  A: Management confirms HIS is a strong, high-performing attractive asset, but believes it can grow faster and unlock more shareholder value as a standalone business or as part of a dedicated healthcare IT player, especially to capitalize on the fast emerging AI opportunity in autonomous coding that will require different investment and innovation prioritization than Solventum's current focus. The company has passed the two-year anniversary of its spin from 3M, which removes barriers to pursuing this portfolio action, and has been receiving inbound interest from third parties for some time. The process is still at an early stage, as the company has only just completed the analysis confirming separation is the right path.

• Q: If HIS separation results in significant proceeds to Solventum, how will management allocate that capital, and will it change the company's M&A strategy?

  A: The company will maintain a balanced capital allocation approach, and after maintaining its current solid investment grade credit rating (and paying down a portion of debt if needed), the majority of any proceeds will be directed toward shareholder return initiatives. The company's tuck-in focused M&A strategy will not change: management will continue pursuing small, strategic acquisitions that fit its existing growth playbook, and has no plans to pursue large-scale transformational acquisitions even with additional balance sheet capacity.

• Q: What drove the upward guidance revision for 2026, and what is the expected quarterly cadence for the rest of the year after the Q2 advanced orders?

  A: The first half of 2026 delivered 4% normalized organic growth, which was at the high end of the company's prior guidance range, giving management confidence to raise the full-year range. After the $125 million in Q2 advanced orders reverse mostly in Q3, the company expects Q3 organic growth to land in the -3% to -4% range, and Q4 organic growth to return to 3% to 4% positive growth, resulting in flat growth for the second half overall and clearing out all the advanced order timing noise by the end of the year. Management noted that the high end of the 2026 ex-SKU guidance already hits the bottom of the original long-range plan that was targeted for 2028.

• Q: After ERP cutover is fully complete, how will Solventum redeploy freed up resources, and what is the impact on future growth?

  A: The ERP cutover has required significant time and focus from the company's top talent across all levels of the organization to resolve unexpected implementation issues, which has pulled focus away from core initiatives. Once complete, freed up talent and cost savings will be redeployed to the company's core growth driver areas and existing cost savings programs, accelerating innovation, adoption, and margin expansion going forward.